144 related articles for article (PubMed ID: 10706891)
1. Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer.
Stiff P; Chen B; Franklin W; Oldenberg D; Hsi E; Bayer R; Shpall E; Douville J; Mandalam R; Malhotra D; Muller T; Armstrong RD; Smith A
Blood; 2000 Mar; 95(6):2169-74. PubMed ID: 10706891
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy.
Engelhardt M; Douville J; Behringer D; Jähne A; Smith A; Henschler R; Lange W
Bone Marrow Transplant; 2001 Feb; 27(3):249-59. PubMed ID: 11277172
[TBL] [Abstract][Full Text] [Related]
3. Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer.
Bachier CR; Gokmen E; Teale J; Lanzkron S; Childs C; Franklin W; Shpall E; Douville J; Weber S; Muller T; Armstrong D; LeMaistre CF
Exp Hematol; 1999 Apr; 27(4):615-23. PubMed ID: 10210319
[TBL] [Abstract][Full Text] [Related]
4. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
Williams SF; Lee WJ; Bender JG; Zimmerman T; Swinney P; Blake M; Carreon J; Schilling M; Smith S; Williams DE; Oldham F; Van Epps D
Blood; 1996 Mar; 87(5):1687-91. PubMed ID: 8634412
[TBL] [Abstract][Full Text] [Related]
5. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy.
Shpall EJ; LeMaistre CF; Holland K; Ball E; Jones RB; Saral R; Jacobs C; Heimfeld S; Berenson R; Champlin R
Blood; 1997 Dec; 90(11):4313-20. PubMed ID: 9373242
[TBL] [Abstract][Full Text] [Related]
7. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation.
Pecora AL; Stiff P; LeMaistre CF; Bayer R; Bachier C; Goldberg SL; Parthasarathy M; Jennis AA; Smith AK; Douville J; Chen B; Armstrong RD; Mandalam RK; Preti R
Bone Marrow Transplant; 2001 Aug; 28(3):295-303. PubMed ID: 11535999
[TBL] [Abstract][Full Text] [Related]
9. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.
Weaver CH; Hazelton B; Birch R; Palmer P; Allen C; Schwartzberg L; West W
Blood; 1995 Nov; 86(10):3961-9. PubMed ID: 7579367
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer.
McNiece I; Jones R; Bearman SI; Cagnoni P; Nieto Y; Franklin W; Ryder J; Steele A; Stoltz J; Russell P; McDermitt J; Hogan C; Murphy J; Shpall EJ
Blood; 2000 Nov; 96(9):3001-7. PubMed ID: 11049977
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescue.
Zimmerman TM; Lee WJ; Bender JG; Schilling M; Smith SL; Van Epps DE; Williams SF
Bone Marrow Transplant; 2000 Sep; 26(5):505-10. PubMed ID: 11019839
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
[TBL] [Abstract][Full Text] [Related]
13. Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
Spyridonidis A; Küttler T; Wäsch R; Samek E; Waterhouse M; Behringer D; Bertz H; Finke J
Stem Cells Dev; 2005 Apr; 14(2):213-22. PubMed ID: 15910248
[TBL] [Abstract][Full Text] [Related]
14. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.
Koç ON; Gerson SL; Cooper BW; Dyhouse SM; Haynesworth SE; Caplan AI; Lazarus HM
J Clin Oncol; 2000 Jan; 18(2):307-16. PubMed ID: 10637244
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation.
Canales MA; Arrieta R; Hernández-García MC; Ojeda E; Díez J; Calero F; Aguado MJ; Bustos JG; Hernández-Navarro F
J Hematother Stem Cell Res; 2000 Feb; 9(1):103-9. PubMed ID: 10738978
[TBL] [Abstract][Full Text] [Related]
17. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
[TBL] [Abstract][Full Text] [Related]
18. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
Elias AD; Ayash L; Anderson KC; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S
Blood; 1992 Jun; 79(11):3036-44. PubMed ID: 1350229
[TBL] [Abstract][Full Text] [Related]
19. Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment.
Robinson SN; Freedman AS; Neuberg DS; Nadler LM; Mauch PM
Exp Hematol; 2000 Dec; 28(12):1325-33. PubMed ID: 11146154
[TBL] [Abstract][Full Text] [Related]
20. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
